Ethyl Icosapentate
Ethyl Icosapentate Uses, Dosage, Side Effects, Food Interaction and all others data.
Ethyl Icosapentate or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL). FDA approved on July 26, 2012.
| Trade Name | Ethyl Icosapentate |
| Generic | Icosapent ethyl |
| Icosapent ethyl Other Names | E-EPA, Eicosapentaenoic acid ethyl ester, Ethyl eicosapentaenoate, Ethyl icosapentate, Ethyl-EPA, Icosapent ethyl, Timnodonic acid ethyl ester |
| Type | |
| Formula | C22H34O2 |
| Weight | Average: 330.5042 Monoisotopic: 330.255880332 |
| Groups | Approved, Investigational, Nutraceutical |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Ethyl Icosapentate is an ethyl ester of eicosapentaenoic acid (EPA) that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.
Ethyl Icosapentate is used as adjunct therapy to reduce triglyceride (TG) levels in adults with severe (>500 mg/dL) hypertriglyceridemia.
Ethyl Icosapentate is also used to associated treatment for these conditions: Severe Hypertriglyceridemia
How Ethyl Icosapentate works
Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.
Toxicity
Ethyl Icosapentate is generally well tolerated and adverse effects are unrelated to treatment.
Food Interaction
- Take with food.
Volume of Distribution
Steady state volume of distribution of active EPA is 88 L
Elimination Route
Ethyl Icosapentate is de-esterfied, converted into active EPA, and then absorbed in the small intestine. It reaches peak plasma concentration in 5 hours post-oral administration. Very little (<1%) is left circulating in the plasma as EPA incorporates into phospholipids, TG's, and cholesteryl esters.
Half Life
The half life of EPA is 89 hours.
Clearance
Total plasma clearance, EPA = 684 mL/hr
Elimination Route
Ethyl Icosapentate is not renally excreted
Innovators Monograph
You find simplified version here Ethyl Icosapentate
